The Association of ERBB2-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer

This cohort study investigates the association between low levels of ERBB2 expression and progression-free survival among patients with HR+/ERBB2− metastatic breast cancer treated with CDK4/6 inhibitors.

Detalles Bibliográficos
Autores principales: Bao, Kelvin K. H., Sutanto, Leone, Tse, Shirley S. W., Man Cheung, Ka, Chan, Jeffrey C. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571658/
https://www.ncbi.nlm.nih.gov/pubmed/34739066
http://dx.doi.org/10.1001/jamanetworkopen.2021.33132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571658/
https://www.ncbi.nlm.nih.gov/pubmed/34739066
http://dx.doi.org/10.1001/jamanetworkopen.2021.33132

Ejemplares similares